Log In
Print this Print this

Copegus, ribavirin (RG964)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSynthetic nucleoside analog
Molecular Target Unknown
Mechanism of ActionUnknown
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsImprove viremia associated with compensated cirrhosis related to HCV infection; Treat chronic hepatitis C virus (HCV) genotype 1, 2 and 3 infection in treatment naïve patients; Treat chronic hepatitis C virus (HCV) infection in interferon-naïve patients; Treat hepatitis C virus (HCV) infection; Treat hepatitis C virus (HCV) infection in treatment-naïve patients
Regulatory Designation
PartnerChugai Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today